Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

35.03 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
From Harmony Biosciences
Via GlobeNewswire
7 Cheap Biotech Stocks With Major Upside Potential
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. 
Via InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
Via Benzinga
Key Takeaways From Harmony Biosciences Analyst Ratings
Via Benzinga
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
HRMY earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with... 
Via Benzinga
Topics Earnings
Exposures Financial
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
From Harmony Biosciences
Via GlobeNewswire
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
Via Benzinga
Analyst Ratings For Harmony Biosciences
Via Benzinga
Updates: HRMY, MELI, SWAV
​​​​​​​Another day, another slew of quarterly update reports for our followed stocks. 
Via Talk Markets
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024
Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently. 
Via InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024
Although the high-flying entities still capture Wall Street’s attention, astute investors should look to undervalued Russell 2000 stocks. 
Via InvestorPlace
NASDAQ:HRMY stands out as a growth opportunity that won't break the bank.
Looking for growth without the hefty price tag? Consider NASDAQ:HRMY. 
Via Chartmill
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 6 Analysts
Via Benzinga
NASDAQ:HRMY: good value for what you're paying.
In a market where value is scarce, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Investors should take notice of NASDAQ:HRMY—it offers a great deal for the fundamentals it presents.
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Why Harmony Biosciences Stock Got Slammed Today
The commercial-stage company was dinged by a bearish new take from a researcher. 
Via The Motley Fool
2023 Year In Review
The S&P 500 had a strong year in 2023, returning about 24% to investors from the beginning of the year to the end. Some of that was a bounce back from a poor 2022 when it was down over 11%. 
Via Talk Markets
Topics Stocks
Exposures US Equities
NASDAQ:HRMY is showing good growth, while it is not too expensive.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. 
Via InvestorPlace
NASDAQ:HRMY, an undervalued stock with good fundamentals.
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Russell 2000 Front-Runners: 3 Stocks to Keep an Eye On
Although Russell 2000 stocks may operate in the lightweight category, these entities could potentially provide a knockout punch. 
Via InvestorPlace
Looking for growth without the hefty price tag? Consider NASDAQ:HRMY.
Investors seeking growth at a reasonable cost should explore HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY). 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS